Inari's FlowTriever catheter nudges into the data pole position to treat pulmonary embolisms | $NARI
SUMMARY
Pulmonary embolisms (PEs) are blood clots that develop in one or more arteries in the lung. When a PE forms, patients experience shortness of breath, chest pain and cough. Most often, these symptoms and the clot can be treated with blood-thinning and clot-dissolving drugs. Not all patients, however, respond to the drugs and surgical intervention may be required.
Inari Medical, Inc. (NASDAQ:NARI), a medtech company specializing in treating venous disease, attempts to resolve PEs by directing its FlowTriever catheter to the clot, which then captures and removes the clot. Diagnoses of PEs can be difficult and customized treatments may arise for different locations of PEs. Inari appears to have the pole position in the data race for catheter-based approaches. The company expects to release interim data from its PEERLESS trial in the second half of 2024.
Key catalysts
Data from the randomized, controlled PEERLESS trial to treat pulmonary embolisms (PEs)
Key catalyst dates
2H 2024